CMPS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.02
Percentage change -0.49	%

Peers: MNMD ATAI CYBN GHRS RLMD AXSM MNOV XENE PRTA CARA

| Held by: ARKG IBB SURI PSIL SBIO GWX BBC DARP BIB IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.20	Insider Own	8.40%	Shs Outstand	68.41M	Perf Week	-4.05%
Market Cap	275.73M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	-31.64%	Shs Float	62.68M	Perf Month	-8.62%
Income	-145.02M	PEG	-	EPS next Q	-0.63	Inst Own	39.55%	Short Float	6.18%	Perf Quarter	-41.00%
Sales	0.00M	P/S	-	EPS this Y	-1.96%	Inst Trans	30.76%	Short Ratio	4.31	Perf Half Y	-30.64%
Book/sh	2.82	P/B	1.43	EPS next Y	10.15%	ROA	-53.09%	Short Interest	3.88M	Perf Year	-53.94%
Cash/sh	3.03	P/C	1.33	EPS next 5Y	3.40%	ROE	-64.99%	52W Range	3.86 - 12.75	Perf YTD	-53.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-65.58%	52W High	-68.39%	Beta	2.26
Dividend TTM	-	Quick Ratio	8.91	Sales past 5Y	0.00%	Gross Margin	-	52W Low	4.54%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	8.91	EPS Y/Y TTM	15.09%	Oper. Margin	-	RSI (14)	37.75	Volatility	7.47% 6.31%
Employees	186	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.10
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	14.97%	Payout	-	Rel Volume	0.26	Prev Close	4.05
Sales Surprise	-	EPS Surprise	1.81%	Sales Q/Q	-	Earnings	Oct 31 BMO	Avg Volume	899.29K	Price	4.03
SMA20	-6.68%	SMA50	-19.02%	SMA200	-41.65%	Trades		Volume	238,244	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	RBC Capital Mkts	Outperform	$23
Apr-01-24	Initiated	Morgan Stanley	Overweight	$30
Dec-12-23	Initiated	Deutsche Bank	Buy	$16
Nov-21-22	Resumed	Berenberg	Buy	$33
Nov-01-22	Initiated	Loop Capital	Buy	$34
Oct-29-21	Initiated	Oppenheimer	Outperform	$50
Jul-13-21	Initiated	Citigroup	Buy	$67
Jun-28-21	Initiated	Maxim Group	Buy	$70
May-11-21	Initiated	Cantor Fitzgerald	Overweight	$71
Apr-01-21	Initiated	ROTH Capital	Buy	$88
Oct-14-20	Initiated	H.C. Wainwright	Buy	$65
Oct-13-20	Initiated	Evercore ISI	Outperform
Oct-13-20	Initiated	Cowen	Outperform
Oct-13-20	Initiated	Canaccord Genuity	Buy	$80
Oct-13-20	Initiated	Berenberg	Buy	$50

Show Previous Ratings

Dec-18-24 06:30AM	Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) (Business Wire) -6.43%
Nov-29-24 08:57PM	Is Your Mind Ready to Consider Investing in Psychedelics Stocks? (Motley Fool)
Nov-25-24 04:00PM	Compass Pathways to Participate in December Investor Conferences (Business Wire)
Nov-14-24 07:44AM	Compass Pathways to participate in Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-02-24 09:25AM	Compass Pathways cuts 30% of workforce on Phase 3 trial delays (TipRanks)
11:00AM	Loading…
Nov-01-24 11:00AM	Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Oct-31-24 09:00PM	Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript (Motley Fool) -23.10%
08:03AM	Compass delays anticipated psilocybin readout, cuts staff (BioPharma Dive)
06:30AM	Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Oct-24-24 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 (Business Wire)
Sep-23-24 07:00AM	Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Aug-28-24 06:00AM	Compass Pathways to participate in three investor conferences in September (GlobeNewswire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-19-24 07:13AM	More promise for psilocybin in depression but safety remains a concern (Clinical Trials Arena)
Aug-12-24 12:47PM	FDA Rejection of MDMA Therapy Isnt End of Psychedelic-Drug Candidates (Barrons.com)
08:00AM	Loading…
Aug-06-24 08:00AM	COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 11:30PM	Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript (Motley Fool) -9.83%
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-28-24 06:05PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-24-24 07:01AM	Compass Pathways to announce second quarter financial results on August 1, 2024 (GlobeNewswire)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +9.39%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 06:30AM	Compass Pathways appoints Lori Englebert as Chief Commercial Officer (GlobeNewswire)
Jun-24-24 04:01PM	Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-12-24 06:25AM	Should You Buy the Dip on Compass Pathways Stock? (Motley Fool) +7.04%
Jun-10-24 08:25AM	Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. (Motley Fool) -5.62%
Jun-09-24 06:14PM	After FDA setback, psychedelic drugmakers distance themselves from a pioneer (Washington Post)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal)
May-21-24 08:05AM	These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring (Motley Fool)
10:43AM	Loading…
May-13-24 10:43AM	COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:45AM	Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript (Motley Fool)
May-08-24 06:45AM	Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
06:30AM	Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder (GlobeNewswire)
May-03-24 04:58PM	Compass Pathways to announce first quarter financial results on May 8, 2024 (GlobeNewswire)
May-02-24 06:30AM	Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment (GlobeNewswire)
Apr-29-24 06:30AM	Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (GlobeNewswire)
Apr-01-24 04:01PM	Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.35%
Mar-31-24 05:47PM	20 Most Depressed Countries in Asia (Insider Monkey)
Mar-28-24 08:00AM	Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors (GlobeNewswire) -12.42%
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-05-24 09:59AM	15 Highest Paying Jobs with a Psychology Degree (Insider Monkey) -5.48%
08:52AM	20 Countries with Most Antidepressant Users in the World (Insider Monkey)
Mar-01-24 09:08AM	COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.78%
Feb-29-24 03:30PM	Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript (Motley Fool) -16.98%
07:34AM	Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements (GuruFocus.com)
07:00AM	Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 12:33PM	Penny Power Players: 3 Stocks to Watch in the Microcap Arena (InvestorPlace) +9.64%
Feb-26-24 04:01PM	Compass Pathways to participate in upcoming TD Cowen investor conference (GlobeNewswire)
Feb-22-24 04:01PM	Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024 (GlobeNewswire)
Feb-21-24 03:06PM	Mental Health Mavericks: 3 Stocks Changing the Game (InvestorPlace)
Feb-19-24 07:00AM	Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. (Motley Fool)
Feb-02-24 04:27PM	As investors pile into psychedelics, idealism gives way to pharma economics (Associated Press Finance)
Jan-31-24 04:01PM	Compass Pathways to participate in upcoming Oppenheimer investor conference (GlobeNewswire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire) +7.87%
Jan-16-24 08:00AM	Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved (GlobeNewswire)
Jan-09-24 01:56PM	Therapys New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution (InvestorPlace)
Jan-08-24 11:47AM	3 Big New Catalysts for Psychedelics Stocks in 2024 (Motley Fool) +11.07%
Jan-05-24 08:00AM	Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement (GlobeNewswire) -6.97%
Dec-29-23 08:42AM	5 Best Psychedelic Stocks to Buy (Insider Monkey)
Dec-19-23 04:05PM	Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder (GlobeNewswire) -5.87%
Dec-13-23 02:55PM	25 Best Online Psychology Degree Programs Heading Into 2024 (Insider Monkey) -6.62%
Dec-07-23 07:00AM	Compass Pathways appoints Teri Loxam as Chief Financial Officer (GlobeNewswire) +7.94%
Dec-06-23 04:00PM	Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry (GlobeNewswire)
Dec-05-23 04:09PM	Investing in Mental Health: 3 Stocks in the Wellness Space (InvestorPlace) -7.38%
Nov-24-23 08:00AM	Compass Pathways to participate in upcoming Evercore investor conference (GlobeNewswire) +6.61%
Nov-15-23 04:00AM	Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center (GlobeNewswire)
Nov-05-23 11:26AM	COMPASS Pathways plc (NASDAQ:CMPS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 11:39AM	Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript (Motley Fool) +7.73%
Nov-02-23 08:51AM	Compass Pathways PLC (CMPS) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 08:00AM	COMPASS Pathways announces CFO transition (GlobeNewswire)
Oct-24-23 04:01PM	COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire) +6.86%
Oct-12-23 09:15AM	The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It (News Direct)
Oct-06-23 09:00AM	COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care (News Direct)
Sep-27-23 03:17PM	Dont Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher (InvestorPlace)
Sep-22-23 08:30AM	How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space (News Direct)
Sep-19-23 09:25AM	One Year Into Kabir Naths Leadership, Compass Pathways (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing (News Direct)
Sep-18-23 04:31PM	COMPASS Pathways appoints Daphne Karydas to its Board of Directors (GlobeNewswire)
Sep-13-23 09:00AM	Whats Spurring The Growth Of The Psychedelics Market And How One Company Is Helping As Part Of The Vanguard In This Emerging Field (News Direct)
Sep-06-23 04:00AM	COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression (GlobeNewswire)
Aug-29-23 04:30PM	COMPASS Pathways to participate in upcoming September investor conferences (GlobeNewswire)
Aug-26-23 07:50AM	3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street (Motley Fool)
Aug-21-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +11.23%
Aug-16-23 08:58AM	COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors (GlobeNewswire) +18.46%
Aug-04-23 12:00AM	Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript (Motley Fool) -5.01%
Aug-03-23 07:00AM	COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-31-23 08:32AM	COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023 (GlobeNewswire)
Jul-28-23 10:15AM	This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock (Motley Fool)
Jul-25-23 04:00AM	First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine (GlobeNewswire)
Jul-17-23 04:00AM	COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology (GlobeNewswire)
Jul-13-23 04:00AM	Opinion paper calls for clarity on the definition of psychedelic-assisted therapy using psilocybin (GlobeNewswire) +5.19%
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
07:00AM	American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies (GlobeNewswire)
Jul-05-23 07:00AM	COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital (GlobeNewswire)
Jul-01-23 10:04AM	Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? (Motley Fool)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
Jun-16-23 07:00AM	COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences (GlobeNewswire)

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATAI Life Sciences N.V.	10% Owner	Sep 26 '24	Sale	6.05	2,660,000	16,093,000	6,905,774	Sep 27 08:00 PM
Malievskaia Ekaterina	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,931,687	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,929,413	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 20 '24	Sale	7.89	6,704	52,908	3,938,313	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 20 '24	Sale	7.89	6,703	52,900	3,940,587	May 22 04:22 PM
Goldsmith George Jay	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,929,413	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,931,687	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 20 '24	Sale	7.89	6,704	52,908	3,938,313	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 20 '24	Sale	7.89	6,703	52,900	3,940,587	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 03 '24	Sale	8.82	18,762	165,456	3,947,290	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 03 '24	Sale	8.82	18,761	165,448	3,945,017	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 02 '24	Sale	8.29	9,622	79,768	3,963,778	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 02 '24	Sale	8.29	9,621	79,760	3,966,052	May 06 06:31 PM
Malievskaia Ekaterina	10% Owner	May 03 '24	Sale	8.82	18,762	165,456	3,947,290	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 03 '24	Sale	8.82	18,761	165,448	3,945,017	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 02 '24	Sale	8.29	9,622	79,768	3,963,778	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 02 '24	Sale	8.29	9,621	79,760	3,966,052	May 06 06:30 PM
Goldsmith George Jay	10% Owner	Apr 16 '24	Sale	8.53	23,881	203,679	3,986,523	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 16 '24	Sale	8.53	23,880	203,670	3,984,250	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,973,400	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,975,673	Apr 18 04:12 PM
Malievskaia Ekaterina	10% Owner	Apr 16 '24	Sale	8.53	23,881	203,679	3,986,523	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 16 '24	Sale	8.53	23,880	203,670	3,984,250	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,975,673	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,973,400	Apr 18 04:10 PM
Goldsmith George Jay	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,008,130	Apr 02 04:23 PM
Goldsmith George Jay	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,010,404	Apr 02 04:23 PM
Malievskaia Ekaterina	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,010,404	Apr 02 04:22 PM
Malievskaia Ekaterina	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,008,130	Apr 02 04:22 PM
Malievskaia Ekaterina	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,036,154	Apr 01 08:55 AM
Malievskaia Ekaterina	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,033,880	Apr 01 08:55 AM
Goldsmith George Jay	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,033,880	Apr 01 08:55 AM
Goldsmith George Jay	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,036,154	Apr 01 08:55 AM
Goldsmith George Jay	Director	Mar 13 '24	Sale	10.80	17,203	185,877	4,059,630	Mar 14 09:12 PM
Goldsmith George Jay	Director	Mar 13 '24	Sale	10.80	17,203	185,877	4,061,904	Mar 14 09:12 PM
Goldsmith George Jay	Director	Mar 12 '24	Sale	10.58	15,740	166,534	4,076,833	Mar 14 09:12 PM
Goldsmith George Jay	Director	Mar 12 '24	Sale	10.58	15,740	166,534	4,079,107	Mar 14 09:12 PM
Malievskaia Ekaterina	Director	Mar 13 '24	Sale	10.80	17,203	185,877	4,061,904	Mar 14 09:08 PM
Malievskaia Ekaterina	Director	Mar 13 '24	Sale	10.80	17,203	185,877	4,059,630	Mar 14 09:08 PM
Malievskaia Ekaterina	Director	Mar 12 '24	Sale	10.58	15,740	166,534	4,079,107	Mar 14 09:08 PM
Malievskaia Ekaterina	Director	Mar 12 '24	Sale	10.58	15,740	166,534	4,076,833	Mar 14 09:08 PM
Malievskaia Ekaterina	Director	Feb 26 '24	Sale	10.45	17,765	185,602	4,094,847	Feb 27 05:33 PM
Malievskaia Ekaterina	Director	Feb 26 '24	Sale	10.45	17,765	185,602	4,092,573	Feb 27 05:33 PM
Malievskaia Ekaterina	Director	Feb 23 '24	Sale	10.06	11,863	119,335	4,112,612	Feb 27 05:33 PM
Malievskaia Ekaterina	Director	Feb 23 '24	Sale	10.06	11,862	119,325	4,110,338	Feb 27 05:33 PM
Goldsmith George Jay	Director	Feb 26 '24	Sale	10.45	17,765	185,602	4,092,573	Feb 27 05:29 PM
Goldsmith George Jay	Director	Feb 26 '24	Sale	10.45	17,765	185,602	4,094,847	Feb 27 05:29 PM
Goldsmith George Jay	Director	Feb 23 '24	Sale	10.06	11,863	119,335	4,112,612	Feb 27 05:29 PM
Goldsmith George Jay	Director	Feb 23 '24	Sale	10.06	11,862	119,325	4,110,338	Feb 27 05:29 PM
Malievskaia Ekaterina	Director	Feb 07 '24	Sale	10.56	22,794	240,753	4,124,475	Feb 08 04:52 PM
Malievskaia Ekaterina	Director	Feb 07 '24	Sale	10.56	22,794	240,753	4,122,200	Feb 08 04:52 PM
Malievskaia Ekaterina	Director	Feb 06 '24	Sale	10.59	19,853	210,315	4,144,994	Feb 08 04:52 PM
Malievskaia Ekaterina	Director	Feb 06 '24	Sale	10.59	19,852	210,304	4,147,269	Feb 08 04:52 PM
Goldsmith George Jay	Director	Feb 07 '24	Sale	10.56	22,794	240,753	4,122,200	Feb 08 04:51 PM
Goldsmith George Jay	Director	Feb 07 '24	Sale	10.56	22,794	240,753	4,124,475	Feb 08 04:51 PM
Goldsmith George Jay	Director	Feb 06 '24	Sale	10.59	19,853	210,315	4,144,994	Feb 08 04:51 PM
Goldsmith George Jay	Director	Feb 06 '24	Sale	10.59	19,852	210,304	4,147,269	Feb 08 04:51 PM
Goldsmith George Jay	Director	Jan 22 '24	Sale	8.35	25,750	215,033	4,169,745	Jan 23 05:54 PM
Goldsmith George Jay	Director	Jan 22 '24	Sale	8.35	25,750	215,033	4,172,404	Jan 23 05:54 PM
Goldsmith George Jay	Director	Jan 19 '24	Sale	7.99	20,206	161,448	4,195,495	Jan 23 05:54 PM
Goldsmith George Jay	Director	Jan 19 '24	Sale	7.99	20,205	161,440	4,198,154	Jan 23 05:54 PM
Malievskaia Ekaterina	Director	Jan 22 '24	Sale	8.35	25,750	215,033	4,172,404	Jan 23 05:51 PM
Malievskaia Ekaterina	Director	Jan 22 '24	Sale	8.35	25,750	215,033	4,169,745	Jan 23 05:51 PM
Malievskaia Ekaterina	Director	Jan 19 '24	Sale	7.99	20,206	161,448	4,195,495	Jan 23 05:51 PM
Malievskaia Ekaterina	Director	Jan 19 '24	Sale	7.99	20,205	161,440	4,198,154	Jan 23 05:51 PM
Goldsmith George Jay	Director	Jan 02 '24	Sale	9.00	25,750	231,706	4,237,459	Jan 04 04:15 PM
Goldsmith George Jay	Director	Jan 02 '24	Sale	9.00	25,750	231,706	4,240,117	Jan 04 04:15 PM
Goldsmith George Jay	Director	Jan 03 '24	Sale	8.74	21,758	190,226	4,215,701	Jan 04 04:15 PM
Goldsmith George Jay	Director	Jan 03 '24	Sale	8.74	21,758	190,226	4,218,359	Jan 04 04:15 PM
Malievskaia Ekaterina	Director	Jan 02 '24	Sale	9.00	25,750	231,706	4,240,117	Jan 04 04:14 PM
Malievskaia Ekaterina	Director	Jan 02 '24	Sale	9.00	25,750	231,706	4,237,459	Jan 04 04:14 PM
Malievskaia Ekaterina	Director	Jan 03 '24	Sale	8.74	21,758	190,226	4,218,359	Jan 04 04:14 PM
Malievskaia Ekaterina	Director	Jan 03 '24	Sale	8.74	21,758	190,226	4,215,701	Jan 04 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Compass Pathways Plc ADR

Upgrade your FINVIZ experience